Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026
Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Fineline Cube Jul 23, 2026
Company Deals

3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem

Fineline Cube Apr 16, 2026

3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China’s...

Company Deals

Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment

Fineline Cube Apr 16, 2026

Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of...

Others

Bayer AG Secures NMPA Approval for Hyrnuo (Sevabertinib) to Treat HER2-Mutant NSCLC in China

Fineline Cube Apr 16, 2026

Bayer AG (ETR: BAYN) announced that China’s National Medical Products Administration (NMPA) has granted marketing...

Company Deals Drug

Johnson & Johnson Partners with Shanghai Pharmaceuticals for Exclusive Promotion of Paliperidone Palmitate Long-Acting Injection in China

Fineline Cube Apr 16, 2026

Johnson & Johnson (J&J, NYSE: JNJ) has entered into an exclusive marketing promotion agreement with...

Company Deals

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations

Fineline Cube Apr 15, 2026

Novo Nordisk (NYSE: NVO) announced on April 14, 2026, a strategic partnership with OpenAI that...

Company Drug

Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders

Fineline Cube Apr 15, 2026

Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory...

Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026

The State Council released the “Opinions on Improving the Drug Pricing Mechanism” this week, introducing...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes

Fineline Cube Apr 15, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced the first subject dosing in a Phase III...

Company Deals

AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates

Fineline Cube Apr 15, 2026

AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised...

Company Deals

Autobio Diagnostics Expands Global IVD Footprint with Dual Vietnam Partnerships

Fineline Cube Apr 15, 2026

Autobio Diagnostics Co., Ltd. (SHA: 603658) announced this week it has executed separate strategic partnership...

Company Deals

Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma

Fineline Cube Apr 15, 2026

Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with...

Company Deals

UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency

Fineline Cube Apr 15, 2026

UCB (EBR: UCB) announced that the European Commission (EC) has granted marketing approval under exceptional...

Company

Eli Lilly Restructures China Cardiometabolic Division Ahead of Foundayo Oral GLP-1 Launch

Fineline Cube Apr 15, 2026

Eli Lilly and Company’s (NYSE: LLY) China unit announced a comprehensive organizational restructuring and key...

Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Fineline Cube Apr 15, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal

Fineline Cube Apr 15, 2026

Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it...

Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Fineline Cube Apr 15, 2026

Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology...

Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026

Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced positive top-line results from a Phase III...

Company

Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance

Fineline Cube Apr 15, 2026

Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing...

Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Fineline Cube Apr 15, 2026

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National...

Company Drug

Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube Apr 15, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, announced it has received...

Posts pagination

1 … 47 48 49 … 699

Recent updates

  • MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
  • CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer
  • PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments
  • Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
  • OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.